A value-based analysis of hemodynamic support strategies for high-risk heart failure patients undergoing a percutaneous coronary intervention

American Health and Drug Benefits

Volumn 6, Issue 2, 2013, Pages

  Gregory, David ^a   Scotti, Dennis J ^b   de Lissovoy, Gregory ^c   Palacios, Igor ^d   Dixon, Simon ^e   Maini, Brijeshwar ^f   O'Neill, William ^g  

^a Division of ParenteBeard   (United States)

^b FAIRLEIGH DICKINSON UNIVERSITY   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e WILLIAM BEAUMONT HOSPITAL   (United States)

^f Advanced Cardiac and Endovascular Interventional Laboratory   (United States)

^g HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CEREBROVASCULAR DISEASE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HEART FAILURE; HEART HEMODYNAMICS; HIDDEN MARKOV MODEL; HIGH RISK PATIENT; HOSPITAL ADMISSION; HOSPITAL BILLING; HOSPITAL CHARGE; HOSPITAL READMISSION; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; INTERMETHOD COMPARISON; INTRAAORTIC BALLOON PUMP; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT CARE; PERCUTANEOUS CORONARY INTERVENTION; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VENTRICULAR ASSIST DEVICE;

EID: 84877299673     PISSN: 19422962     EISSN: 19422970     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation. 2013;127:e6-e245.
2. Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123:933-944.
3. Lloyd-Jones D, Adams RJ, Brown TM, et al. Executive summary: heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010;121:948-954.
4. Jencks SF, Williams MV, Coleman EA, et al. Rehospitalization among patients in the Medicare fee-for-service program. N Engl J Med. 2009;360:1418-1428.
5. Whellan DJ, Greiner MA, Schulman KA, et al. Costs of inpatient care among Medicare beneficiaries with heart failure, 2001 to 2004. Circ Cardiovasc Qual Outcomes. 2010;3:33-40.
6. Nowicki S, Zembroski D, Pickering L, Nobel J. Reducing Preventable Hospital Readmissions: A Multistakeholder Perspective. New York, NY: North East Business Group on Health; July 2012. www.nebgh.org/publications/HospitalRedadmissionsReport_V2_SinglePages.pdf. Accessed March 20, 2013.
7. Pittsburgh Regional Health Initiative. PRHI Readmission Reduction Guide: A Manual for Preventing Hospitalizations. January 2011. www.prhi.org/documents/ReadmissionReductionGuide-Final2-1-11.pdf. Accessed March 20, 2013.
8. Agency for Healthcare Research and Quality. Care Coordination: National Healthcare Quality Report, 2011. Publication 12-005; February 2011. www.ahrq.gov/qual/nhqr11/chap6.htm. Accessed January 24, 2013.
9. Thiele H, Zeymer U, Neumann FJ, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. 2012;367:1287-1296.
10. Curtis JP, Rathore SS, Wang Y, et al. Use and effectiveness of intra-aortic balloon pumps among patients undergoing high risk percutaneous coronary intervention: insights from the National Cardiovascular Data Registry. Circ Cardiovasc Qual Outcomes. 2012;5:21-30.
11. Patel MR, Smalling RW, Thiele H, et al. Intra-aortic balloon counterpulsation and infarct size in patients with acute anterior myocardial infarction without shock: the CRISP AMI randomized trial. JAMA. 2011;306:1329-1337.
12. Perera D, Stables R, Thomas M, et al. Elective intra-aortic balloon counterpulsation during high-risk percutaneous coronary intervention: a randomized controlled trial. JAMA. 2010;304:867-874.
13. Sjauw KD, Engström AE, Vis MM, et al. A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines? Eur Heart J. 2009;30:459-468.
14. O'Neill WW, Kleiman NS, Moses J, et al. A prospective randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT II study. Circulation. 2012;126:1717-1727.
15. Sjauw KD, Remmelink M, Baan J II, et al. Left ventricular unloading in acute ST-segment elevation myocardial infarction patients is safe and feasible and provides acute and sustained left ventricular recovery. J Am Coll Cardiol. 2008;51:1044-1046.
16. Seyfarth M, Sibbing D, Bauer I, et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol. 2008;52:1584-1588.
17. Stone GW, Mehran R, Dangas G, et al. Differential impact on survival of electrocardiographic Q-wave versus enzymatic myocardial infarction after percutaneous intervention: a device-specific analysis of 7147 patients. Circulation. 2001;104:642-647.
18. Herring B, Song X, Pauly M; US Department of Health and Human Services. Changes in coverage in the individual and group health insurance markets and the effect of health status. April 2008. http://aspe.hhs.gov/daltcp/reports/2008/HIcover.pdf. Accessed March 20, 2013.
19. Jost TS. Loopholes in the Affordable Care Act: regulatory gaps and border crossing techniques and how to address them. Louis UJ Health Law Policy. 2011;5:27-82.
20. The Henry J. Kaiser Family Foundation. Employer Health Benefits 2012 Annual Survey. http://ehbs.kff.org/pdf/2012/8345.pdf. Accessed March 20, 2013.
21. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health care evaluation: report of the ISPOR Task Force on Good Research Practices-modeling studies. Value Health. 2003;6:9-17.
22. Gregory DA, Scotti DJ. A budget impact model to estimate the cost dynamics of treating high-risk heart failure patients with advanced percutaneous cardiac assist devices: the payer perspective. J Manag Care Med. 2013;16:61-69.
23. Levy WC, Mozaffarian D, Linker DT, et al. Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2006;113:1424-1433.
24. Ahn SA, Jong P, Yusuf S, et al. Early versus delayed enalapril in patients with left ventricular systolic dysfunction: impact on morbidity and mortality 15 years after the SOLVD trial. J Am Coll Cardiol. 2006;47:1904-1905.
25. Solomon SD, Anavekar N, Skali H, et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation. 2005; 112:3738-3744.
26. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
27. Center for the Evaluation of Value and Risk in Health. Cost Effectiveness Analysis Registry. https://research.tufts-nemc.org/cear4/. Accessed January 24, 2013.
28. Mahoney EM, Greenberg D, Lavelle TA, et al. Cost and cost-effectiveness of carotid stenting versus endarterectomy for patients at increased surgical risk: results from the SAPPHIRE trial. Catheter Cardiovasc Interv. 2011;77:463-472.
29. Tsevat J, Goldman L, Soukup JR, et al. Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Making. 1993;13:161-165.
30. Goeree R, Blackhouse G, Petrovic R, et al. Cost of stroke in Canada: a 1-year prospective study. J Med Econ. 2005;8:147-167.
31. Chaplin S, Scuffham PA, Alon M, et al. Secondary prevention after PCI: the cost-effectiveness of statin therapy in the Netherlands. Neth Heart J. 2004;12:331-336.
32. Greving JP, Visseren FL, de Wit GA, Algra A. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis. BMJ. 2011;342:d1672.
33. Regier DA, Sunderji R, Lynd LD, et al. Cost-effectiveness of self-managed versus physician-managed oral anticoagulation therapy. CMAJ. 2006;174:1847-1852.
34. Alehagen U, Rahmqvist M, Paulsson T, Levin LA. Quality-adjusted life year weights among elderly patients with heart failure. Eur J Heart Fail. 2008;10:1033-1039.
35. Bakhai A, Stone GW, Mahoney E, et al. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV trial. J Am Coll Cardiol. 2006;48:253-261.
36. Bakhai A, Stone GW, Grines CL, et al. Cost-effectiveness of coronary stenting and abciximab for patients with acute myocardial infarction: results from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trial. Circulation. 2003;108:2857-2863.
37. Cohen DJ, Taira DA, Berezin R, et al. Cost-effectiveness of coronary stenting in acute myocardial infarction: results from the Stent Primary Angioplasty in Myocardial Infarction (Stent-PAMI) trial. Circulation. 2001;104:3039-3045.
38. Post PN, Stiggelbout AM, Wakker PP. The utility of health states after stroke: a systemic review of the literature. Stroke. 2001;32:1425-1429.
39. Cutler DM, Rosen AB, Vijan S. The value of medical spending in the United States, 1960-2000. N Engl J Med. 2006;355:920-927.
40. Doan QV, Chiou CF, Dubois RW. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. J Manag Care Pharm. 2006;12:555-569.
41. Ohsfeldt RL, Gandhi SK, Smolen LJ, et al. Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial. J Med Econ. 2010;13:428-437.
42. Reynolds MR, Magnuson EA, Wang K, et al. Cost-effectiveness of transcatheter aortic valve replacement compared with standard care among inoperable patients with severe aortic stenosis: results from the placement of aortic transcatheter valves (PARTNER) trial (cohort B). Circulation. 2012;125:1102-1109.
43. Cohen DJ, Lavelle TA, Van Hout B, et al. Economic outcomes of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with left main or three-vessel coronary artery disease: one-year results from the SYNTAX trial. Catheter Cardiovasc Interv. 2012;79:198-209.
44. Bischof M, Briel M, Bucher HC, et al. Cost-effectiveness of drug-eluting stents in a US Medicare setting: a cost-utility analysis with 3-year clinical follow-up data. Value Health. 2009;12:649-656.
45. US Department of Health and Human Services. National Strategy for Quality Improvement in Health Care. March 2011. www.healthcare.gov/news/reports/nationalqualitystrategy032011.pdf. Accessed March 20, 2013